脑胶质瘤DNA甲基化临床意义及研究进展

doi:10.3969/j.issn.1672-6731.2022.09.013

摘要/Abstract

摘要： 脑胶质瘤存在特异性CpG岛甲基化表型（G-CIMP），与异柠檬酸脱氢酶（IDH）突变密切相关。经替莫唑胺治疗的胶质瘤复发时存在一种超突变，O⁶-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化水平有助于预测超突变风险，从而为临床决策提供依据。全基因组DNA甲基化分析业已成为中枢神经系统肿瘤分类的有效辅助方法，本文综述DNA甲基化分析在胶质瘤中的研究进展，并探讨其临床意义。

关键词: 神经胶质瘤, 异柠檬酸脱氢酶, 突变, DNA甲基化, 综述

Abstract: Glioma has a specific CpG island methylator phenotype (G-CIMP), which is closely related to isocitrate dehydrogenase (IDH) mutation. A hypermutation is present at recurrence in temozolomide-treated gliomas, and O⁶-methylguanine-DNA methyltransferase (MGMT) promoter methylation levels can help predict the risk of hypermutation to inform clinical decision. Whole genome DNA methylation analysis has become an effective auxiliary method for the classification of central nervous system tumors. This article reviews the research progress of DNA methylation analysis in glioma and discusses its clinical significance.

Key words: Glioma, Isocitrate dehydrogenase, Mutation, DNA methylation, Review

姚盈盈, 王雷明, 滕梁红. 脑胶质瘤DNA甲基化临床意义及研究进展[J]. 中国现代神经疾病杂志, 2022, 22(9): 823-828.

YAO Ying-ying, WANG Lei-ming, TENG Liang-hong. Clinical significance and research progress of DNA methylation in glioma[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2022, 22(9): 823-828.

http://journal11.magtechjournal.com/cjcnn/CN/Y2022/V22/I9/823

参考文献

[1] Dor Y, Cedar H.Principles of DNA methylation and their implications for biology and medicine[J].Lancet, 2018, 392:777-786.
[2] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW.The 2016 World Health Organization Classification of Tumors of the Central Nervous System:a summary[J].Acta Neuropathol, 2016, 131:803-820.
[3] Gujar H, Weisenberger DJ, Liang G.The roles of human DNA methyltransferases and their isoforms in shaping the epigenome[J].Genes (Basel), 2019, 10:172.
[4] Aoki K, Natsume A.Overview of DNA methylation in adult diffuse gliomas[J].Brain Tumor Pathol, 2019, 36:84-91.
[5] Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP.CpG island methylator phenotype in colorectal cancer[J].Proc Natl Acad Sci USA, 1999, 96:8681-8686.
[6] Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K; Cancer Genome Atlas Research Network.Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma[J].Cancer Cell, 2010, 17:510-522.
[7] Malta TM, de Souza CF, Sabedot TS, Silva TC, Mosella MS, Kalkanis SN, Snyder J, Castro AVB, Noushmehr H.Glioma CpG island methylator phenotype (G-CIMP):biological and clinical implications[J].Neuro Oncol, 2018, 20:608-620.
[8] Ruiz-Rodado V, Malta TM, Seki T, Lita A, Dowdy T, Celiku O, Cavazos-Saldana A, Li A, Liu Y, Han S, Zhang W, Song H, Davis D, Lee S, Trepel JB, Sabedot TS, Munasinghe J, Yang C, Herold-Mende C, Gilbert MR, Cherukuri MK, Noushmehr H, Larion M.Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas[J].Neuro Oncol, 2020, 22:480-492.
[9] Laird PW.How epigenomics broke the mold:an interview with Peter W Laird[J].Epigenomics, 2022, 14:303-308.
[10] Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, Noushmehr H, Iavarone A, Verhaak RG; TCGA Research Network.Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma[J].Cell, 2016, 164:550-563.
[11] de Souza CF, Sabedot TS, Malta TM, Stetson L, Morozova O, Sokolov A, Laird PW, Wiznerowicz M, Iavarone A, Snyder J, deCarvalho A, Sanborn Z, McDonald KL, Friedman WA, Tirapelli D, Poisson L, Mikkelsen T, Carlotti CG Jr, Kalkanis S, Zenklusen J, Salama SR, Barnholtz-Sloan JS, Noushmehr H.A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence[J].Cell Rep, 2018, 23:637-651.
[12] Nomura M, Saito K, Aihara K, Nagae G, Yamamoto S, Tatsuno K, Ueda H, Fukuda S, Umeda T, Tanaka S, Takayanagi S, Otani R, Nejo T, Hana T, Takahashi S, Kitagawa Y, Omata M, Higuchi F, Nakamura T, Muragaki Y, Narita Y, Nagane M, Nishikawa R, Ueki K, Saito N, Aburatani H, Mukasa A.DNA demethylation is associated with malignant progression of lower-grade gliomas[J].Sci Rep, 2019, 9:1903.
[13] Tomar MS, Kumar A, Srivastava C, Shrivastava A.Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance[J].Biochim Biophys Acta Rev Cancer, 2021, 1876:188616.
[14] Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, Lindeman NI, Wen PY, Chakravarti A, Mehta MP, Hegi ME, Stupp R, Aldape KD, Zadeh G.MGMT promoter methylation status testing to guide therapy for glioblastoma:refining the approach based on emerging evidence and current challenges[J].Neuro Oncol, 2019, 21:167-178.
[15] Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ferrer-Luna R, Ramkissoon SH, Dubois F, Bellamy C, Currimjee N, Bonardi J, Qian K, Ho P, Malinowski S, Taquet L, Jones RE, Shetty A, Chow KH, Sharaf R, Pavlick D, Albacker LA, Younan N, Baldini C, Verreault M, Giry M, Guillerm E, Ammari S, Beuvon F, Mokhtari K, Alentorn A, Dehais C, Houillier C, Laigle-Donadey F, Psimaras D, Lee EQ, Nayak L, McFaline-Figueroa JR, Carpentier A, Cornu P, Capelle L, Mathon B, Barnholtz-Sloan JS, Chakravarti A, Bi WL, Chiocca EA, Fehnel KP, Alexandrescu S, Chi SN, Haas-Kogan D, Batchelor TT, Frampton GM, Alexander BM, Huang RY, Ligon AH, Coulet F, Delattre JY, Hoang-Xuan K, Meredith DM, Santagata S, Duval A, Sanson M, Cherniack AD, Wen PY, Reardon DA, Marabelle A, Park PJ, Idbaih A, Beroukhim R, Bandopadhayay P, Bielle F, Ligon KL.Mechanisms and therapeutic implications of hypermutation in gliomas[J].Nature, 2020, 580:517-523.
[16] Mathur R, Zhang Y, Grimmer MR, Hong C, Zhang M, Bollam S, Petrecca K, Clarke J, Berger MS, Phillips JJ, Oberheim-Bush NA, Molinaro AM, Chang SM, Costello JF.MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence[J].Neuro Oncol, 2020, 22:1580-1590.
[17] Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJM, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS, Costello JF.Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma[J].Science, 2014, 343:189-193.
[18] Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim BS.Temozolomide induced hypermutation in glioma:evolutionary mechanisms and therapeutic opportunities[J].Front Oncol, 2019, 9:41.
[19] Aslan K, Turco V, Blobner J, Sonner JK, Liuzzi AR, Núñez NG, De Feo D, Kickingereder P, Fischer M, Green E, Sadik A, Friedrich M, Sanghvi K, Kilian M, Cichon F, Wolf L, Jähne K, von Landenberg A, Bunse L, Sahm F, Schrimpf D, Meyer J, Alexander A, Brugnara G, Röth R, Pfleiderer K, Niesler B, von Deimling A, Opitz C, Breckwoldt MO, Heiland S, Bendszus M, Wick W, Becher B, Platten M.Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas[J].Nat Commun, 2020, 11:931.
[20] Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09):a randomised, open-label, phase 3 trial[J].Lancet, 2019, 393:678-688.
[21] Lazaridis L, Schäfer N, Teuber-Hanselmann S, Blau T, Schmidt T, Oster C, Weller J, Tzaridis T, Pierscianek D, Keyvani K, Kleinschnitz C, Stuschke M, Scheffler B, Deuschl C, Sure U, Herrlinger U, Kebir S, Glas M.Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma[J].J Cancer Res Clin Oncol, 2020, 146:787-792.
[22] Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ.Lomustine and bevacizumab in progressive glioblastoma[J].N Engl J Med, 2017, 377:1954-1963.
[23] Heynckes S, Daka K, Franco P, Gaebelein A, Frenking JH, Doria-Medina R, Mader I, Delev D, Schnell O, Heiland DH.Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme[J].BMC Cancer, 2019, 19:117.
[24] Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I.Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma[J].Nat Med, 2019, 25:470-476.
[25] Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW.The 2021 WHO Classification of Tumors of the Central Nervous System:a summary[J].Neuro Oncol, 2021, 23:1231-1251.
[26] Yang XJ, Yin HF, Li Z, Yu SZ.Chinese version of simplified table of 2021 WHO Classification of Tumors of the Central Nervous System (fifth edition) and translational interpretations[J].Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2021, 21:746-750.[杨学军, 尹洪芳, 李智, 于士柱.2021年世界卫生组织中枢神经系统肿瘤分类(第五版)简表中译版及说明[J].中国现代神经疾病杂志, 2021, 21:746-750.]
[27] Kling T, Wenger A, Beck S, Carén H.Validation of the MethylationEPIC BeadChip for fresh-frozen and formalin-fixed paraffin-embedded tumours[J].Clin Epigenetics, 2017, 9:33.
[28] Verburg N, Barthel FP, Anderson KJ, Johnson KC, Koopman T, Yaqub MM, Hoekstra OS, Lammertsma AA, Barkhof F, Pouwels PJW, Reijneveld JC, Rozemuller AJM, Beliën JAM, Boellaard R, Taylor MD, Das S, Costello JF, Vandertop WP, Wesseling P, de Witt Hamer PC, Verhaak RGW.Spatial concordance of DNA methylation classification in diffuse glioma[J].Neuro Oncol, 2021, 23:2054-2065.
[29] Li Z.Introduction of newly identified tumor types in the 2021 WHO Classification of Tumors of the Central Nervous System (fifth edition)[J].Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2021, 21:769-782.[李智.2021年世界卫生组织中枢神经系统肿瘤分类(第五版)新增肿瘤介绍[J].中国现代神经疾病杂志, 2021, 21:769-782.]
[30] Fernandez AF, Assenov Y, Martin-Subero JI, Balint B, Siebert R, Taniguchi H, Yamamoto H, Hidalgo M, Tan AC, Galm O, Ferrer I, Sanchez-Cespedes M, Villanueva A, Carmona J, Sanchez-Mut JV, Berdasco M, Moreno V, Capella G, Monk D, Ballestar E, Ropero S, Martinez R, Sanchez-Carbayo M, Prosper F, Agirre X, Fraga MF, Graña O, Perez-Jurado L, Mora J, Puig S, Prat J, Badimon L, Puca AA, Meltzer SJ, Lengauer T, Bridgewater J, Bock C, Esteller M.A DNA methylation fingerprint of 1628 human samples[J].Genome Res, 2012, 22:407-419.
[31] Kristensen BW, Priesterbach-Ackley LP, Petersen JK, Wesseling P.Molecular pathology of tumors of the central nervous system[J].Ann Oncol, 2019, 30:1265-1278.
[32] Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Müller HL, Rutkowski S, von Hoff K, Frühwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM.DNA methylation-based classification of central nervous system tumours[J].Nature, 2018, 555:469-474.
[33] Suwala AK, Stichel D, Schrimpf D, Maas SLN, Sill M, Dohmen H, Banan R, Reinhardt A, Sievers P, Hinz F, Blattner-Johnson M, Hartmann C, Schweizer L, Boldt HB, Kristensen BW, Schittenhelm J, Wood MD, Chotard G, Bjergvig R, Das A, Tabori U, Hasselblatt M, Korshunov A, Abdullaev Z, Quezado M, Aldape K, Harter PN, Snuderl M, Hench J, Frank S, Acker T, Brandner S, Winkler F, Wesseling P, Pfister SM, Reuss DE, Wick W, von Deimling A, Jones DTW, Sahm F.Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1[J].Acta Neuropathol, 2021, 142:179-189.
[34] Ferreyra Vega S, Olsson Bontell T, Corell A, Smits A, Jakola AS, Carén H.DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas[J].Clin Epigenetics, 2021, 13:102.
[35] Wenger A, Ferreyra Vega S, Kling T, Bontell TO, Jakola AS, Carén H.Intratumor DNA methylation heterogeneity in glioblastoma:implications for DNA methylation-based classification[J].Neuro Oncol, 2019, 21:616-627.
[36] Nassiri F, Chakravarthy A, Feng S, Shen SY, Nejad R, Zuccato JA, Voisin MR, Patil V, Horbinski C, Aldape K, Zadeh G, De Carvalho DD.Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes[J].Nat Med, 2020, 26:1044-1047.
[37] Li J, Zhao S, Lee M, Yin Y, Li J, Zhou Y, Ballester LY, Esquenazi Y, Dashwood RH, Davies PJA, Parsons DW, Li XN, Huang Y, Sun D.Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma[J].Sci Adv, 2020, 6:eabb5427.
[38] Lane R, Simon T, Vintu M, Solkin B, Koch B, Stewart N, Benstead-Hume G, Pearl FMG, Critchley G, Stebbing J, Giamas G.Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping[J].Commun Biol, 2019, 2:315.
[39] Maire CL, Fuh MM, Kaulich K, Fita KD, Stevic I, Heiland DH, Welsh JA, Jones JC, Görgens A, Ricklefs T, Dührsen L, Sauvigny T, Joosse SA, Reifenberger G, Pantel K, Glatzel M, Miklosi AG, Felce JH, Caselli M, Pereno V, Reimer R, Schlüter H, Westphal M, Schüller U, Lamszus K, Ricklefs FL.Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification[J].Neuro Oncol, 2021, 23:1087-1099.
[40] Sabedot TS, Malta TM, Snyder J, Nelson K, Wells M, deCarvalho AC, Mukherjee A, Chitale DA, Mosella MS, Sokolov A, Asmaro KP, Robin A, Rosenblum ML, Mikkelsen T, Rock J, Poisson LM, Lee I, Walbert T, Kalkanis S, Iavarone A, Castro AV, Noushmehr H.A serum-based DNA methylation assay provides accurate detection of glioma[J].Neuro Oncol, 2021, 23:1494-1508.

选择文件类型/文献管理软件名称

选择包含的内容

2 脑胶质瘤DNA甲基化临床意义及研究进展

Clinical significance and research progress of DNA methylation in glioma

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	薛蓉, 张轩. 睡眠障碍对脑血管病的影响[J]. 中国现代神经疾病杂志, 2023, 23(8): 659-662.
[2]	张鹏, 陈涛, 许莉. 成人失眠认知行为疗法关键技术与流程改进建议[J]. 中国现代神经疾病杂志, 2023, 23(8): 663-667.
[3]	张轩, 薛蓉. 特发性快速眼动睡眠期行为障碍向神经系统变性疾病转化的生物学标志物研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 668-673.
[4]	刘引, 汤永红, 翟锦霞, 邱媛. 慢性低度炎症与睡眠障碍研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 674-677.
[5]	于洁洋, 张亚男, 李惠敏, 黄真灿, 李宛儒, 王赞. 发作性睡病与焦虑研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 678-682.
[6]	库成心, 邓丽影, 谢亮. 缺血性卒中继发日间过度思睡研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 683-686.
[7]	姜佳凤, 赵莲花, 赵伟. 褪黑素在阿尔茨海默病病理损害机制中的作用[J]. 中国现代神经疾病杂志, 2023, 23(8): 687-692.
[8]	黄沛, 王刚. 功能性帕金森综合征诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(8): 738-741.
[9]	洪涛, 唐斌. 如何成为一名优秀的颅底外科医师[J]. 中国现代神经疾病杂志, 2023, 23(7): 571-574.
[10]	张庆硕, 宋丹丹, 周世越, 张金璐, 韩晓旭, 许顺良. 功能性步态障碍诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(7): 604-609.
[11]	潘希娟, 邢英琦, 刘玉梅. 脑小血管病影像学评分方法[J]. 中国现代神经疾病杂志, 2023, 23(7): 633-637.
[12]	俞淑凤, 李宁, 徐健, 王鹏. 颈动脉漂浮血栓相关缺血性卒中诊断与治疗进展[J]. 中国现代神经疾病杂志, 2023, 23(7): 638-642.
[13]	李跃文, 褚先舟, 李娟, 秦艳, 吴桐, 陈先文. BSCL2基因c.455A>G突变致远端型遗传性运动神经病V型一家系[J]. 中国现代神经疾病杂志, 2023, 23(7): 643-647.
[14]	魏俊吉. 神经外科重症医学规范化诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(6): 477-478.
[15]	杜倩, 邓素君, 邹姗, 金珺, 周青山. 宏基因组第二代测序技术在重症中枢神经系统感染中的应用[J]. 中国现代神经疾病杂志, 2023, 23(6): 479-484.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 脑胶质瘤DNA甲基化临床意义及研究进展

Clinical significance and research progress of DNA methylation in glioma

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价